Liraglutide Reduces Pain in Diabetic Neuropathy Mice, Especially in Enriched Environments

What the researchers found

Liraglutide (0.4 mg/kg daily for 10 days) did not reduce blood sugar in streptozotocin-diabetic mice but significantly alleviated pain behavior. In the formalin test, liraglutide-treated mice in an enriched environment showed dramatically lower second-phase pain responses compared to standard housing [2.00 vs 29.00 seconds, p=0.016]. Liraglutide reduced neopterin levels (an inflammation marker) compared to untreated diabetic controls. The glutamine/glutamate ratio was significantly higher with liraglutide treatment or enriched environment compared to diabetic controls (p=0.003 and p=0.002, respectively).

Why it matters

Diabetic neuropathy affects up to 50% of diabetes patients and current treatments only manage symptoms. The finding that liraglutide reduces neuropathic pain independently of blood sugar control suggests GLP-1 drugs may have direct neuroprotective effects. The environmental enrichment finding adds an intriguing non-pharmacological dimension to neuropathy management.

How the study worked

Type 1 diabetes was induced in mice with streptozotocin (150 mg/kg i.p.). Mice received liraglutide (0.4 mg/kg daily i.p. for 10 days starting day 8 post-induction) and were housed in either standard laboratory or enriched environments. Pain was assessed using formalin and von Frey tests. Blood glucose, neopterin, and glutamine/glutamate ratios were measured.

What this study cannot tell us

This is a mouse study using chemically-induced type 1 diabetes, which may not perfectly model human diabetic neuropathy. Liraglutide did not lower blood sugar, limiting its relevance as a diabetes treatment in this model. The 10-day treatment period is short. The von Frey results were mixed (decreased threshold), suggesting complex effects on different pain modalities. Sample sizes were not reported in the abstract.

How to read the evidence

This is a preclinical animal study using a chemically-induced diabetes model. While the findings are interesting, especially the environmental enrichment interaction, the results require human validation and the mixed von Frey results add complexity.

When this study was published

Published in 2024, this study contributes to the rapidly expanding understanding of GLP-1 receptor agonists' extra-pancreatic effects, particularly in the nervous system.

The bigger picture

There is growing evidence that GLP-1 receptor agonists have neuroprotective effects beyond glucose control — including in Alzheimer's disease, Parkinson's disease, and now diabetic neuropathy. This study adds to that body of evidence and uniquely demonstrates that environmental factors can synergize with pharmacological treatment, suggesting multimodal approaches to neuropathy.

Questions still open

• Could GLP-1 drugs be used specifically for diabetic neuropathy pain management in humans, independent of their glucose-lowering effects?
• What is the mechanism by which environmental enrichment enhances liraglutide's analgesic effect?
• Would longer treatment duration or higher doses of liraglutide produce more consistent pain relief across different pain modalities?

Common questions

Read the original research

Antinociceptive Behavior, Glutamine/Glutamate, and Neopterin in Early-Stage Streptozotocin-Induced Diabetic Neuropathy in Liraglutide-Treated Mice under a Standard or Enriched Environment.

International journal of molecular sciences, 25(19)

Citation

Gateva, Pavlina; Hristov, Milen; Ivanova, Natasha; Vasileva, Debora; Ivanova, Alexandrina; Sabit, Zafer; Bogdanov, Todor; Apostolova, Sonia; Tzoneva, Rumiana. (2024). Antinociceptive Behavior, Glutamine/Glutamate, and Neopterin in Early-Stage Streptozotocin-Induced Diabetic Neuropathy in Liraglutide-Treated Mice under a Standard or Enriched Environment.. International journal of molecular sciences, 25(19). https://doi.org/10.3390/ijms251910786